Literature DB >> 821005

Long-term administration of corticosteroids in myasthenia gravis.

J D Mann, T R Johns, J F Campa.   

Abstract

Favorable results were obtained in 30 patients with myasthenia gravis treated initially with high daily doses of prednisone and subsequently maintained on lower doses for a protracted period. In 45 incidents of treatment, complete remission occurred in 69 percent, marked improvement in 20 percent, and moderate improvement in 17 percent. Nineteen patients proceeded to thymectomy, with negligible morbidity and sustained improvement. In four patients, it was possible to discontinue prednisone 1 year or more after thymectomy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 821005     DOI: 10.1212/wnl.26.8.729

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

Review 1.  Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014.

Authors:  Yoshihisa Kadota; Hirotoshi Horio; Takeshi Mori; Noriyoshi Sawabata; Taichiro Goto; Shin-ichi Yamashita; Takeshi Nagayasu; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-01-22

2.  Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.

Authors:  M J Kupersmith; G Ying
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

3.  Myasthenia Gravis Presenting as Persistent Unilateral Ptosis with Facial Droop.

Authors:  Sean K Golden; Chris J Reiff; Chris J Painter; Michael D Repplinger
Journal:  J Emerg Med       Date:  2015-03-19       Impact factor: 1.484

4.  Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis.

Authors:  Laura Díez-Porras; Christian Homedes; Maria Antonia Alberti; Valentina Vélez-Santamaría; Carlos Casasnovas
Journal:  Sci Rep       Date:  2020-08-11       Impact factor: 4.379

5.  Clinically Worsening Myasthenia-Related Respiratory Distress Notwithstanding Normal Markers of Respiratory Function.

Authors:  Hamza Ashraf; Vlad Vayzband
Journal:  Cureus       Date:  2021-05-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.